Glycosylases
Alpha-Mannosidosis is a lysosomal storage disorder caused by deficient activity of the enzyme alpha-D-mannosidase (EC 3.2.1.24). In humans it is known to be caused by an autosomal recessive genetic mutation. causes sugar build up and impairs cell function. Complete absence of functional enzyme leads to death during early childhood due to deterioration of the central nervous system. Enzyme with low residual activity leads to a milder type of the disease, with symptoms like reduced hearing, mental retardation, susceptibility to bacterial infections and skeletal deformities[1]. Miglitol (Axon 2067), an alpha-glucosidase (EC 3.2.1.20) inhibitor, is an oral antihyperglycaemic agent is indicated for the treatment of patients with type 2 diabetes mellitus[2].
[1] Adult alpha-mannosidosis: clinical progression in the absence of demyelination. A. Gutschalk,I. Harting, M. Cantz, C. Springer, K. Rohrschneider, H.M. Meinck. Neurology. 2004, 63, 1744-1746.
[2] Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. L.J. Scott, C.M. Spencer. Drugs. 2000, 9, 521-549.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 4210 | Voglibose | α-Glucosidase inhibitor | €80.00 | |
| 2934 | TH 5487 | Potent and selective active-site OGG1 inhibitor | €125.00 | |
| 3136 | Oseltamivir phosphate | Selective and orally available inhibitor of influenza virus neuraminidases | €50.00 | |
| 3353 | OATD-01 | First-in-class, highly potent and selective CHIT1 inhibitor | €130.00 | |
| 3260 | OAT-1441 | First highly potent, selective and orally bioavailable hAMCase inhibitor | €220.00 | |
| 2067 | Miglitol | α-glucosidase inhibitor; oral anti-diabetic | €55.00 | |
| 2617 | GSK837149 | Selective inhibitor of human fatty acid synthase (FAS) | €120.00 | |
| 3517 | DSRM-3716 | Potent and selective SARM1 NADase inhibitor | €70.00 | |
| N0015 | COTC | Glyoxylase-I inhibitor, HeLa cells growth inhibitor and Ehrlich ascites carcinoma | Inquire | |
| 3570 | CD38 inhibitor compound 78c | Potent, specific, reversible, and uncompetitive inhibitor of CD38 | €140.00 | |
| 3182 | BI 99990 | Negative control of BI 99179 as a selective inhibitor of type I fatty acid synthase | €130.00 | |
| 3181 | BI 99179 | Potent, selective and orally active inhibitor of type I fatty acid synthase (FAS) | €150.00 | |
| 1730 | (+)-Kifunensine | α-mannosidase inhibitor | €120.00 | |